COAG
NASDAQ HealthcareHemab Therapeutics Holdings, Inc. - Common Stock
Biotechnology
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $53.59 |
|---|---|
| 成交量 | 204,693 |
| 市值 | 2.50B |
| RSI（14日） | 55.9 |
| 50日均线 | $39.02 |
| 52周最高 | $55.42 |
| 52周最低 | $23.00 |
| Forward P/E | -21.12 |
| Price / Book | 5.51 |
🎯 投资策略评分
COAG 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (57/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 COAG in your text
粘贴任何文章、记录或帖子 — 工具将提取 COAG 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-08-17.